14/08/2021
As I have gotten to understand one of the cardinal reasons there are misconceptions surrounding this covid-19 vaccines is the lack of adequate information for the Vaccinees; our health practitioners administering these vaccines are not charged with the informative prowess to have our people informed at every segment of the vaccination process..
Vaccines reduce risks of getting a disease by working with your body’s natural defenses to build protection. When you get a vaccine, your immune system:
Recognizes the invading germ, such as the virus or bacteria.
Produces antibodies. Antibodies are proteins produced naturally by the immune system to fight disease.
Remembers the disease and how to fight it. If you are then exposed to the germ in the future, your immune system can quickly destroy it before you become unwell.
The vaccine is therefore a safe and clever way to produce an immune response in the body, without causing illness.
Our immune systems are designed to remember. Once exposed to one or more doses of a vaccine, we typically remain protected against a disease for years, decades or even a lifetime. This is what makes vaccines so effective. Rather than treating a disease after it occurs, vaccines prevent us in the first instance from getting sick..
Vaccines work by training and preparing the body’s natural defences – the immune system – to recognize and fight off viruses and bacteria. If the body is exposed to those disease-causing pathogens later, it will be ready to destroy them quickly – which prevents illness.
When a person gets vaccinated against a disease, their risk of infection is also reduced – so they’re also less likely to transmit the virus or bacteria to others. As more people in a community get vaccinated, fewer people remain vulnerable, and there is less possibility for an infected person to pass the pathogen on to another person. Lowering the possibility for a pathogen to circulate in the community protects those who cannot be vaccinated (due to health conditions, like allergies, or their age) from the disease targeted by the vaccine.
'Herd immunity', also known as 'population immunity', is the indirect protection from an infectious disease that happens when immunity develops in a population either through vaccination or through previous infection. Herd immunity does not mean unvaccinated or individuals who have not previously been infected are themselves immune. Instead, herd immunity exists when individuals who are not immune, but live in a community with a high proportion of immunity, have a reduced risk of disease as compared to non-immune individuals living in a community with a small proportion of immunity.
In communities with high immunity, the non-immune people have a lower risk of disease than they otherwise would, but their reduced risk results from the immunity of people in the community in which they are living (i.e. herd immunity) not because they are personally immune. Even after herd immunity is first reached and a reduced risk of disease among unimmunized people is observed, this risk will keep falling if vaccination coverage continues to increase. When vaccine coverage is very high, the risk of disease among those who are non-immune can become similar to those who are truly immune.
WHO supports achieving 'herd immunity' through vaccination, not by allowing a disease to spread through a population, as this would result in unnecessary cases and deaths.
For COVID-19, a new disease causing a global pandemic, many vaccines are in development and some are in the early phase of rollout, having demonstrated safety and efficacy against disease. The proportion of the population that must be vaccinated against COVID-19 to begin inducing herd immunity is not known. This is an important area of research and will likely vary according to the community, the vaccine, the populations prioritized for vaccination, and other factors.
Herd immunity is an important attribute of vaccines against polio, rotavirus, pneumococcus, Haemophilus influenzae type B, yellow fever, meningococcus and numerous other vaccine preventable diseases.
WHO and its partners are committed to accelerating the development of COVID-19 vaccines while maintaining the highest standards on safety. Why it's true that the vaccines were speedily developed and produced, the aspect of Safety and efficacy remains paramount.
In the past, vaccines have been developed through a series of steps that can take many years. Now, given the urgent need for COVID-19 vaccines, unprecedented financial investments and scientific collaborations are changing how vaccines are developed. This means that some of the steps in the research and development process have been happening in parallel, while still maintaining strict clinical and safety standards. For example, some clinical trials are evaluating multiple vaccines at the same time. However, this does not make the studies any less rigorous.
In this study, the researchers comprehensively characterized the early kinetics and magnitude of immunoglobulin G (IgG) antibody responses in the test subjects against the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) protein. The researchers graphically presented the kinetic response of anti-S-RBD antibodies in those who received the vaccine without or with previous SARS-CoV-2 infection.
Blood type is not the only factor in disease severity. How much virus you were exposed to, your age, plus any of your underlying health conditions also affects the course and severity of the disease. Say, for example, you and your friend who have the same susceptibility are both sharing a bus with someone who has asymptomatic COVID-19. Your friend sits next to the person infected. You sit 7 feet away from both of them. Your friend would have a worse case of COVID-19 because they were infected with more virus. We call this the viral load. "Masks are important because they filter out some of the virus and decreases the viral load, which makes the infection less severe," An infection with a lower viral load makes a positive difference in clinical infection in all people.
The question researchers are trying to answer is why blood type matters. One theory is that antibodies may play a role. You may know that blood type A individuals can't donate blood to people with type B blood. That's because of a particular type of antibody they make that attacks other red blood cells. Type O individuals have anti-A and anti-B antibodies, while type A individuals only have one kind: anti-B antibodies. Similarly, type B individuals only have anti-A antibodies. Perhaps having both anti-A and anti-B antibodies gives type O individuals the ability to minimize the disease.
We don't know the answer, which is why ongoing research is so important.
In this study, the researchers comprehensively characterized the early kinetics and magnitude of immunoglobulin G (IgG) antibody responses in the test subjects against the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) protein. The graphically presented the kinetic response of anti-S-RBD antibodies in those who received the vaccine without or with previous SARS-CoV-2 infection.
I wish this can be done by many health workers inorder to clear the myth surrounding this covid-19 vaccines...I urge all hand on desk to adequately inform the many Vaccinees.As I have gotten to understand one of the cardinal reasons there are misconceptions surrounding this covid-19 vaccines is the lack of adequate information for the Vaccinees; our health practitioners administering these vaccines are not charged with the informative prowess to have our people informed at every segment of the vaccination process..
Vaccines reduce risks of getting a disease by working with your body’s natural defenses to build protection. When you get a vaccine, your immune system:
Recognizes the invading germ, such as the virus or bacteria.
Produces antibodies. Antibodies are proteins produced naturally by the immune system to fight disease.
Remembers the disease and how to fight it. If you are then exposed to the germ in the future, your immune system can quickly destroy it before you become unwell.
The vaccine is therefore a safe and clever way to produce an immune response in the body, without causing illness.
Our immune systems are designed to remember. Once exposed to one or more doses of a vaccine, we typically remain protected against a disease for years, decades or even a lifetime. This is what makes vaccines so effective. Rather than treating a disease after it occurs, vaccines prevent us in the first instance from getting sick..
Vaccines work by training and preparing the body’s natural defences – the immune system – to recognize and fight off viruses and bacteria. If the body is exposed to those disease-causing pathogens later, it will be ready to destroy them quickly – which prevents illness.
When a person gets vaccinated against a disease, their risk of infection is also reduced – so they’re also less likely to transmit the virus or bacteria to others. As more people in a community get vaccinated, fewer people remain vulnerable, and there is less possibility for an infected person to pass the pathogen on to another person. Lowering the possibility for a pathogen to circulate in the community protects those who cannot be vaccinated (due to health conditions, like allergies, or their age) from the disease targeted by the vaccine.
'Herd immunity', also known as 'population immunity', is the indirect protection from an infectious disease that happens when immunity develops in a population either through vaccination or through previous infection. Herd immunity does not mean unvaccinated or individuals who have not previously been infected are themselves immune. Instead, herd immunity exists when individuals who are not immune, but live in a community with a high proportion of immunity, have a reduced risk of disease as compared to non-immune individuals living in a community with a small proportion of immunity.
In communities with high immunity, the non-immune people have a lower risk of disease than they otherwise would, but their reduced risk results from the immunity of people in the community in which they are living (i.e. herd immunity) not because they are personally immune. Even after herd immunity is first reached and a reduced risk of disease among unimmunized people is observed, this risk will keep falling if vaccination coverage continues to increase. When vaccine coverage is very high, the risk of disease among those who are non-immune can become similar to those who are truly immune.
WHO supports achieving 'herd immunity' through vaccination, not by allowing a disease to spread through a population, as this would result in unnecessary cases and deaths.
For COVID-19, a new disease causing a global pandemic, many vaccines are in development and some are in the early phase of rollout, having demonstrated safety and efficacy against disease. The proportion of the population that must be vaccinated against COVID-19 to begin inducing herd immunity is not known. This is an important area of research and will likely vary according to the community, the vaccine, the populations prioritized for vaccination, and other factors.
Herd immunity is an important attribute of vaccines against polio, rotavirus, pneumococcus, Haemophilus influenzae type B, yellow fever, meningococcus and numerous other vaccine preventable diseases.
WHO and its partners are committed to accelerating the development of COVID-19 vaccines while maintaining the highest standards on safety. Why it's true that the vaccines were speedily developed and produced, the aspect of Safety and efficacy remains paramount.
In the past, vaccines have been developed through a series of steps that can take many years. Now, given the urgent need for COVID-19 vaccines, unprecedented financial investments and scientific collaborations are changing how vaccines are developed. This means that some of the steps in the research and development process have been happening in parallel, while still maintaining strict clinical and safety standards. For example, some clinical trials are evaluating multiple vaccines at the same time. However, this does not make the studies any less rigorous.
In this study, the researchers comprehensively characterized the early kinetics and magnitude of immunoglobulin G (IgG) antibody responses in the test subjects against the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) protein. The researchers graphically presented the kinetic response of anti-S-RBD antibodies in those who received the vaccine without or with previous SARS-CoV-2 infection.
Blood type is not the only factor in disease severity. How much virus you were exposed to, your age, plus any of your underlying health conditions also affects the course and severity of the disease. Say, for example, you and your friend who have the same susceptibility are both sharing a bus with someone who has asymptomatic COVID-19. Your friend sits next to the person infected. You sit 7 feet away from both of them. Your friend would have a worse case of COVID-19 because they were infected with more virus. We call this the viral load. "Masks are important because they filter out some of the virus and decreases the viral load, which makes the infection less severe," An infection with a lower viral load makes a positive difference in clinical infection in all people.
The question researchers are trying to answer is why blood type matters. One theory is that antibodies may play a role. You may know that blood type A individuals can't donate blood to people with type B blood. That's because of a particular type of antibody they make that attacks other red blood cells. Type O individuals have anti-A and anti-B antibodies, while type A individuals only have one kind: anti-B antibodies. Similarly, type B individuals only have anti-A antibodies. Perhaps having both anti-A and anti-B antibodies gives type O individuals the ability to minimize the disease.
We don't know the answer, which is why ongoing research is so important.
In this study, the researchers comprehensively characterized the early kinetics and magnitude of immunoglobulin G (IgG) antibody responses in the test subjects against the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) protein. The graphically presented the kinetic response of anti-S-RBD antibodies in those who received the vaccine without or with previous SARS-CoV-2 infection.
I wish this can be done by many health workers inorder to clear the myth surrounding this covid-19 vaccines...I urge all hand on desk to adequately inform the many Vaccinees.
